{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-143658","form_type":"8-K","ticker":"IOBTQ","cik":"0001865494","company_name":"IO Biotech, Inc.","filed_at":"2025-06-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.244289+00:00","generated_at":"2026-05-19T01:52:49.970430+00:00","sec_items":["5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"IO Biotech enters CEO severance agreement providing 12-18 months pay and equity vesting","bullets":["Severance pay: 12 months base salary on qualifying termination; 18 months if termination within 6 months pre- or 12 months post-Change in Control.","Equity awards: 12-month vesting acceleration (standard) or 100% vesting at target (Change in Control scenario).","Pro-rated bonus for termination year plus unpaid prior-year bonus; subject to release and non-compete compliance.","CEO Mai-Britt Zocca: addendum to existing service agreement effective June 19, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-143658","json":"https://secwatch.observer/filing/0001193125-25-143658.json","markdown":"https://secwatch.observer/filing/0001193125-25-143658.md","text":"https://secwatch.observer/filing/0001193125-25-143658.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1865494/000119312525143658/0001193125-25-143658-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1865494/000119312525143658/d90779d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T01:52:49.970430+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}